BRIEF published on 10/25/2024 at 09:07, 27 days 5 hours ago ZEAL Network SE's Momentum Drives Guidance Hike Buy Recommendation Growth Trajectory ZEAL Network SE Guidance Increase Q3 Performance
PRESS RELEASE published on 10/25/2024 at 09:02, 27 days 5 hours ago Original-Research: ZEAL Network SE (von NuWays AG): Buy NuWays AG updates recommendation to Buy for ZEAL Network SE, raising target price to EUR 57.00 due to strong sales momentum and profitability outlook NuWays AG Target Price Recommendation ZEAL Network SE Sales Momentum
BRIEF published on 10/24/2024 at 19:39, 27 days 18 hours ago ZEAL Network SE Increases 2024 Financial Forecast Revenue Growth 2024 Outlook Financial Forecast EBITDA Increase ZEAL Network SE
PRESS RELEASE published on 10/24/2024 at 19:34, 27 days 18 hours ago EQS-Adhoc: ZEAL raises guidance ZEAL Network SE raises guidance for 2024 after significant revenue and EBITDA increase in the first nine months due to good jackpots, successful customer acquisition, and higher gross margin Revenue Increase EBITDA Increase 2024 Forecast Guidance ZEAL Network SE
BRIEF published on 10/15/2024 at 09:06, 1 month 6 days ago ZEAL Network SE Benefits from Google Ad Policy Update ZEAL Network SE Google Ad Policy Gambling Regulation Illegal Lottery Market Customer Acquisition Cost
PRESS RELEASE published on 10/15/2024 at 09:01, 1 month 6 days ago Original-Research: ZEAL Network SE (von NuWays AG): Kaufen Research report on ZEAL Network SE by NuWays AG highlights positive impact of Google ad ban on illegal lottery providers, potentially reducing customer acquisition costs NuWays AG Customer Acquisition Costs ZEAL Network SE Illegal Lottery Market Google Ad Ban
BRIEF published on 10/08/2024 at 09:06, 1 month 13 days ago ZEAL Network SE Shows Promising Growth Amid Market Trends Growth Strategy Buy Recommendation Market Share ZEAL Network SE Lottery Brokerage
PRESS RELEASE published on 10/08/2024 at 09:01, 1 month 13 days ago Original-Research: ZEAL Network SE (von NuWays AG): Buy NuWays AG issues a buy recommendation for ZEAL Network SE, highlighting strong market share gains, market trend tailwinds, additional growth opportunities, and operating leverage Buy Recommendation NuWays AG ZEAL Network SE Market Share Gains Operating Leverage
BRIEF published on 10/01/2024 at 09:07, 1 month 20 days ago ZEAL Network SE Anticipates Solid Q3 Performance Q3 Results EBITDA Growth ZEAL Network SE User Activity Lottery Stakes
PRESS RELEASE published on 10/01/2024 at 09:02, 1 month 20 days ago Original-Research: ZEAL Network SE (von NuWays AG): Kaufen ZEAL Network SE's Q3 performance analyzed by NuWays AG, predicting solid results despite normalized lottery demand. Detailed insights into Lotto 6aus49 and EuroJackpot stakes provided NuWays AG ZEAL Network SE Q3 Performance Lottery Demand Lotto 6aus49
Published on 11/21/2024 at 14:00, 15 minutes ago Demotech, Inc. Assigns a Financial Stability Rating(R) of A, Exceptional, to Steadily Insurance Company
Published on 11/21/2024 at 14:00, 15 minutes ago Montara Raises $5.4M to Help Organizations Deliver Better Data Products Faster
Published on 11/21/2024 at 14:00, 15 minutes ago Tevir Capital LP Ltd. Updates Early Warning Reporting in Respect of VerticalScope Holdings Inc.
Published on 11/21/2024 at 13:30, 45 minutes ago AirIQ Announces September 30, 2024 Quarterly Results Company Reports Double-Digit Growth in Recurring Revenue
Published on 11/21/2024 at 12:35, 1 hour 40 minutes ago audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 2 hours ago Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 06:58, 7 hours 17 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 55 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 20 hours 30 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 20 hours 30 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 6 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
